A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
NCT05358691 is a phase 1 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it was withdrawn. It studies AN0025 in Lung Cancer Stage III. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2024 and a primary completion date of 1 Dec 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05358691 |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Lung Cancer Stage III |
| Drugs | AN0025 |
| Start | 1 Nov 2024 |
| Primary completion | 1 Dec 2027 |
| Study completion | 1 Jun 2028 |
| Last update posted | 16 Apr 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rutgers Cancer Institute of New Jersey
New Brunswick
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05358691
Each answer restates registry values shown on this page.
What is NCT05358691?
NCT05358691 is a phase 1 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies AN0025 in Lung Cancer Stage III.
Who leads NCT05358691?
The registry names Salma K Jabbour, MD (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.
Where does NCT05358691 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05358691 study?
The registered drug and biological interventions are AN0025.
When did NCT05358691 end?
The registry lists a primary completion date of 1 Dec 2027 and a study completion date of 1 Jun 2028. The sponsor last updated the record on 16 Apr 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.